Axol Bioscience develops and supplies high-quality induced pluripotent stem cell (iPSC)-derived cells, reagents, and specialist services to pharmaceutical, biotechnology, contract research organizations, and academic institutions worldwide.
The company focuses on providing physiologically relevant iPSC-derived disease models and scalable cell manufacturing to support drug discovery and disease research across neuroscience, ophthalmology, and cardiovascular domains.
Leadership & Board
Currently, no data available
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$3M
Total Amount Raised$3M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$3M
Latest Funding Amount$3M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.